These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 31353004

  • 1. Efficacy and Safety of Ultrathin, Bioresorbable-Polymer Sirolimus-Eluting Stents Versus Thin, Durable-Polymer Everolimus-Eluting Stents for Coronary Revascularization of Patients With Diabetes Mellitus.
    Waksman R, Shlofmitz E, Windecker S, Koolen JJ, Saito S, Kandzari D, Kolm P, Lipinski MJ, Torguson R.
    Am J Cardiol; 2019 Oct 01; 124(7):1020-1026. PubMed ID: 31353004
    [Abstract] [Full Text] [Related]

  • 2. Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus- versus paclitaxel-eluting stents pooled analysis from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials.
    Claessen BE, Smits PC, Kereiakes DJ, Parise H, Fahy M, Kedhi E, Serruys PW, Lansky AJ, Cristea E, Sudhir K, Sood P, Simonton CA, Stone GW.
    JACC Cardiovasc Interv; 2011 Nov 01; 4(11):1209-15. PubMed ID: 22115661
    [Abstract] [Full Text] [Related]

  • 3. Targeted therapy with a localised abluminal groove, low-dose sirolimus-eluting, biodegradable-polymer coronary stent - five-year results of the TARGET All Comers randomised clinical trial.
    Lansky AJ, Xu B, Baumbach A, Kelbæk H, van Royen N, Zheng M, Knaapen P, Slagboom T, Johnson TW, Vlachojannis GJ, Arkenbout KE, Holmvang L, Janssens L, Brugaletta S, Naber CK, Schmitz T, Anderson R, Rittger H, Berti S, Barbato E, Toth GG, Maillard L, Valina CM, Buszman PE, Thiele H, Schächinger V, Wijns W.
    EuroIntervention; 2023 Dec 04; 19(10):e844-e855. PubMed ID: 37860860
    [Abstract] [Full Text] [Related]

  • 4. 1-year clinical outcomes of diabetic patients treated with everolimus-eluting bioresorbable vascular scaffolds: a pooled analysis of the ABSORB and the SPIRIT trials.
    Muramatsu T, Onuma Y, van Geuns RJ, Chevalier B, Patel TM, Seth A, Diletti R, García-García HM, Dorange CC, Veldhof S, Cheong WF, Ozaki Y, Whitbourn R, Bartorelli A, Stone GW, Abizaid A, Serruys PW, ABSORB Cohort B Investigators, ABSORB EXTEND Investigators, SPIRIT FIRST Investigators, SPIRIT II Investigators, SPIRIT III Investigators, SPIRIT IV Investigators.
    JACC Cardiovasc Interv; 2014 May 04; 7(5):482-93. PubMed ID: 24746650
    [Abstract] [Full Text] [Related]

  • 5. Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials.
    Stefanini GG, Byrne RA, Serruys PW, de Waha A, Meier B, Massberg S, Jüni P, Schömig A, Windecker S, Kastrati A.
    Eur Heart J; 2012 May 04; 33(10):1214-22. PubMed ID: 22447805
    [Abstract] [Full Text] [Related]

  • 6. Comparison of newer-generation drug-eluting with bare-metal stents in patients with acute ST-segment elevation myocardial infarction: a pooled analysis of the EXAMINATION (clinical Evaluation of the Xience-V stent in Acute Myocardial INfArcTION) and COMFORTABLE-AMI (Comparison of Biolimus Eluted From an Erodible Stent Coating With Bare Metal Stents in Acute ST-Elevation Myocardial Infarction) trials.
    Sabaté M, Räber L, Heg D, Brugaletta S, Kelbaek H, Cequier A, Ostojic M, Iñiguez A, Tüller D, Serra A, Baumbach A, von Birgelen C, Hernandez-Antolin R, Roffi M, Mainar V, Valgimigli M, Serruys PW, Jüni P, Windecker S.
    JACC Cardiovasc Interv; 2014 Jan 04; 7(1):55-63. PubMed ID: 24332419
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Safety and efficacy of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent for the treatment of de novo coronary lesions: two-year results from a prospective patient-level pooled analysis of TARGET trials.
    Gao Z, Zhang R, Xu B, Yang Y, Ma C, Li H, Chen S, Han Y, Yuan Z, Lansky AJ, Guan C, Leon MB, Gao R, TARGET Investigators.
    Catheter Cardiovasc Interv; 2015 Mar 04; 85 Suppl 1():734-43. PubMed ID: 25678281
    [Abstract] [Full Text] [Related]

  • 9. Randomized Prospective Comparison of Everolimus-Eluting vs. Sirolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention　- 3-Year Clinical Outcomes of the EXCELLENT Randomized Trial.
    Park KW, Rhee TM, Kang HJ, Koo BK, Gwon HC, Yoon JH, Lim DS, Chae IH, Han KR, Ahn T, Jeong MH, Jeon DW, Jang YS, Kim HS.
    Circ J; 2018 May 25; 82(6):1566-1574. PubMed ID: 28966335
    [Abstract] [Full Text] [Related]

  • 10. Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents Versus Thin Durable Polymer Everolimus-Eluting Stents.
    Kandzari DE, Koolen JJ, Doros G, Massaro JJ, Garcia-Garcia HM, Bennett J, Roguin A, Gharib EG, Cutlip DE, Waksman R, BIOFLOW V Investigators.
    J Am Coll Cardiol; 2018 Dec 25; 72(25):3287-3297. PubMed ID: 30257191
    [Abstract] [Full Text] [Related]

  • 11. Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents: BIOFLOW V Final 5-Year Outcomes.
    Kandzari DE, Koolen JJ, Doros G, Garcia-Garcia HM, Bennett J, Roguin A, Gharib EG, Cutlip DE, Waksman R, BIOFLOW V Investigators.
    JACC Cardiovasc Interv; 2022 Sep 26; 15(18):1852-1860. PubMed ID: 36137689
    [Abstract] [Full Text] [Related]

  • 12. Comparison of Ultrathin, Bioresorbable-Polymer Sirolimus-Eluting Stents and Thin, Durable-Polymer Everolimus-Eluting Stents in Calcified or Small Vessel Lesions.
    Dan K, Garcia-Garcia HM, Kolm P, Windecker S, Saito S, Kandzari DE, Waksman R.
    Circ Cardiovasc Interv; 2020 Sep 26; 13(9):e009189. PubMed ID: 32895004
    [Abstract] [Full Text] [Related]

  • 13. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents.
    Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PW.
    N Engl J Med; 2007 Mar 08; 356(10):989-97. PubMed ID: 17296825
    [Abstract] [Full Text] [Related]

  • 14. Differential Prognostic Effect Between First- and Second-Generation Drug-Eluting Stents in Coronary Bifurcation Lesions: Patient-Level Analysis of the Korean Bifurcation Pooled Cohorts.
    Lee JM, Hahn JY, Kang J, Park KW, Chun WJ, Rha SW, Yu CW, Jeong JO, Jeong MH, Yoon JH, Jang Y, Tahk SJ, Gwon HC, Koo BK, Kim HS.
    JACC Cardiovasc Interv; 2015 Aug 24; 8(10):1318-1331. PubMed ID: 26315734
    [Abstract] [Full Text] [Related]

  • 15. Five-Year Outcomes in Patients With Diabetes Mellitus Treated With Biodegradable Polymer Sirolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents.
    Iglesias JF, Heg D, Roffi M, Tüller D, Lanz J, Rigamonti F, Muller O, Moarof I, Cook S, Weilenmann D, Kaiser C, Cuculi F, Valgimigli M, Jüni P, Windecker S, Pilgrim T.
    J Am Heart Assoc; 2019 Nov 19; 8(22):e013607. PubMed ID: 31696762
    [Abstract] [Full Text] [Related]

  • 16. Clinical outcome of patients with and without diabetes mellitus after percutaneous coronary intervention with the resolute zotarolimus-eluting stent: 2-year results from the prospectively pooled analysis of the international global RESOLUTE program.
    Silber S, Serruys PW, Leon MB, Meredith IT, Windecker S, Neumann FJ, Belardi J, Widimsky P, Massaro J, Novack V, Yeung AC, Saito S, Mauri L.
    JACC Cardiovasc Interv; 2013 Apr 19; 6(4):357-68. PubMed ID: 23523454
    [Abstract] [Full Text] [Related]

  • 17. Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent Versus Durable-Polymer Everolimus-Eluting Stent for Percutaneous Coronary Revascularization: 2-Year Results of the BIOSCIENCE Trial.
    Zbinden R, Piccolo R, Heg D, Roffi M, Kurz DJ, Muller O, Vuilliomenet A, Cook S, Weilenmann D, Kaiser C, Jamshidi P, Franzone A, Eberli F, Jüni P, Windecker S, Pilgrim T.
    J Am Heart Assoc; 2016 Mar 15; 5(3):e003255. PubMed ID: 26979080
    [Abstract] [Full Text] [Related]

  • 18. Subgroup Analysis Comparing Ultrathin, Bioresorbable Polymer Sirolimus-Eluting Stents Versus Thin, Durable Polymer Everolimus-Eluting Stents in Acute Coronary Syndrome Patients.
    Roguin A, Kandzari DE, Marcusohn E, Koolen JJ, Doros G, Massaro JM, Garcia-Garcia HM, Bennett J, Gharib EG, Cutlip DE, Waksman R.
    Circ Cardiovasc Interv; 2018 Oct 15; 11(10):e007331. PubMed ID: 30354631
    [Abstract] [Full Text] [Related]

  • 19. Long-Term Comparison of Platinum Chromium Everolimus-Eluting Stent vs. Cobalt Chromium Zotarolimus-Eluting Stent　- 3-Year Outcomes From the HOST-ASSURE Randomized Clinical Trial.
    Kim CH, Park KW, Kang J, Park BE, Cha KS, Rhew JY, Jeon HK, Shin ES, Oh JH, Jeong MH, Kim S, Hwang KK, Yoon JH, Lee SY, Park TH, Moon KW, Kwon HM, Hur SH, Ryu JK, Lee BR, Park YW, Chae IH, Kim HS, HOST–ASSURE Investigators.
    Circ J; 2019 Jun 25; 83(7):1489-1497. PubMed ID: 31155604
    [Abstract] [Full Text] [Related]

  • 20. Application of the Academic Research Consortium High Bleeding Risk criteria in patients treated with coronary bioresorbable polymer everolimus-eluting stents: Insights from the POEM trial.
    Popolo Rubbio A, Testa L, Pivato CA, Regazzoli D, Piccolo R, Esposito G, Musto C, Scalia L, Pacchioni A, Briguori C, Lucisano L, De Luca L, Conrotto F, Tartaglia F, Latini AC, Stankowski K, Chiarito M, Sardella G, Indolfi C, Bedogni F, Reimers B, Condorelli G, Stefanini GG.
    Cardiovasc Revasc Med; 2024 Oct 25; 67():77-83. PubMed ID: 38702260
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.